iRhythm Holdings, Inc.
IRTCHealthcareNASDAQMedical Devices · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, iRhythm Holdings, Inc. focuses on Medical Devices services and products. iRhythm Holdings, Inc. iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to. At a $4.03B market cap, iRhythm Holdings, Inc. ranks as a mid-cap company within healthcare. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.
Market Cap
$4.03B
Beta
1.32
P/E (TTM)
—
P/E (Fwd)
100.73
EPS (TTM)
$-0.42
EPS (Fwd)
$1.21
ROE
-9.6%
ROA
0.7%
Cash
$591.3M
Total Debt
$727.3M
Free CF
$81.8M
52W Change
-32.4%
Annual Financials
Cash vs Debt
Where IRTC stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, IRTC finished 0.08% above its 150-day moving average ($122.38) and 9.39% below its 200-day moving average ($135.17). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IRTC overbought or oversold?
At the September 3, 2026 close, IRTC's RSI(14) was 49.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, IRTC has $591.3M in cash with $727.3M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $81.8M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -9.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 0.7% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $410.9M (2022) to $747.1M (2025), reflecting a 82% increase over the period.
As with any equity investment, IRTC carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence iRhythm Holdings, Inc.'s trajectory.